An inhaler (or puffer) is a medical device used for delivering medication into the body via the lungs. It is mainly used in the treatment of asthma and chronic obstructive pulmonary disease. Zanamivir, used to treat influenza, must be administered via inhaler.
To reduce deposition in the mouth and throat, and to reduce the need for precise synchronization of the start of inhalation with actuation of the device, MDIs are sometimes used with a complementary spacer or holding chamber device.
Maps, Directions, and Place Reviews
Types
Metered-dose (MDI)
The most common type of inhaler is the pressurized metered-dose inhaler (MDI) which is made up of 3 standard components- a metal canister, plastic actuator, and a metering valve. H&T Presspart, based in Blackburn, UK, provide over 75% of the world's can and actuator components to the pharmaceutical market. The metering valve is supplied by a number of companies including Aptar and Coster. In MDIs, medication is typically stored in solution in a pressurized canister that contains a propellant, although it may also be a suspension. The MDI canister is attached to a plastic, hand-operated actuator. On activation, the metered-dose inhaler releases a fixed dose of medication in aerosol form. The correct procedure for using an MDI is to first fully exhale, place the mouth-piece of the device into the mouth, and having just started to inhale at a moderate rate, depress the canister to release the medicine. The aerosolized medication is drawn into the lungs by continuing to inhale deeply before holding the breath for 10 seconds to allow the aerosol to settle onto the walls of the bronchittus and other airways of the lung. Some inhalers are made to act instantly in case of an asthma attack, and others are made to act later.
Dry powder (DPI)
Dry powder inhalers release a metered or device-measured dose of powdered medication that is inhaled through a DPI device.
Nebulizers
Nebulizers -- supply the medication as an aerosol created from an aqueous formulation.
Nasal
Nasal inhalers contain decongestant drugs to relieve nasal congestion in the upper respiratory tract. The active ingredient in most decongestants is either pseudoephedrine or phenylephrine. Many are sold over-the-counter without a prescription.[1]
Yellow Inhaler Video
Propellants
In 2009, the FDA banned the use of inhalers that use chlorofluorocarbons (CFC) as propellants. In their place, inhalers now use hydrofluoroalkane (HFA). HFA is not environmentally inert as it is a greenhouse gas but it does not affect the ozone layer. While some asthma sufferers and advocacy groups contend that HFA inhalers are not as effective, published clinical studies indicate CFC and HFA inhalers are equally effective in controlling asthma.
While the impact of CFCs from inhalers on the ozone layer had been minuscule (dwarfed by industrial processes using CFCs,) the FDA in its interpretation of the Montreal Protocol mandated the switch in propellants. Patients expressed concern about the high price of the HFA inhalers as there are no generic versions, whereas generic CFC inhalers had been available.
History
The idea of directly delivering medication into the lungs was based on ancient traditional cures that involved the use of aromatic and medicinal vapours. These did not involve any special devices beyond the apparatus used for burning or heating to produce fumes. Early inhalation devices included one devised by John Mudge in 1778. It had a pewter mug with a hole allowing attachment of a flexible tube. Mudge used it for the treatment of coughs using opium. These devices evolved with modifications by Wolfe, Mackenzie (1872) and better mouth attachments such as by Beigel in 1866. Many of these early inhalers needed heat to vapourize the active chemical ingredient. The benefits of forced expiration and inspiration to treat asthma were noted by J. S. Monell in 1865. Chemicals used in inhalers included ammonia, chlorine, iodine, tar, balsams, turpentine camphor and numerous others in combinations. Julius Mount Bleyer used a variation in 1890 in New York.
In 1968, Robert Wexler of Abbott Laboratories developed the Analgizer, a disposable inhaler that allowed the self-administration of methoxyflurane vapor in air for analgesia. The Analgizer consisted of a polyethylene cylinder 5 inches long and 1 inch in diameter with a 1 inch long mouthpiece. The device contained a rolled wick of polypropylene felt which held 15 milliliters of methoxyflurane.
Because of the simplicity of the Analgizer and the pharmacological characteristics of methoxyflurane, it was easy for patients to self-administer the drug and rapidly achieve a level of conscious analgesia which could be maintained and adjusted as necessary over a period of time lasting from a few minutes to several hours. The 15 milliliter supply of methoxyflurane would typically last for two to three hours, during which time the user would often be partly amnesic to the sense of pain; the device could be refilled if necessary.
The Analgizer was found to be safe, effective, and simple to administer in obstetric patients during childbirth, as well as for patients with bone fractures and joint dislocations, and for dressing changes on burn patients. When used for labor analgesia, the Analgizer allows labor to progress normally and with no apparent adverse effect on Apgar scores. All vital signs remain normal in obstetric patients, newborns, and injured patients. The Analgizer was widely utilized for analgesia and sedation until the early 1970s, in a manner that foreshadowed the patient-controlled analgesia infusion pumps of today. The Analgizer inhaler was withdrawn in 1974, but use of methoxyflurane as a sedative and analgesic continues in Australia and New Zealand in the form of the Penthrox inhaler.
Source of the article : Wikipedia
EmoticonEmoticon